GlassScriptPhysician profile
Kamran Tasharofi
NPI 1174595466
$47,953.43
in general payments reported to CMS, 2019-2025
65 companies · $1,830 in 2025
The $1,830 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,303 · 2020: $2,682 · 2021: $11K · 2022: $8,308 · 2023: $15K · 2024: $4,726 · 2025: $1,830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $6,567 · Travel and Lodging: $819 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,975.00 |
| Food and Beverage | $6,566.67 |
| Travel and Lodging | $818.77 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30,128.75 | 2021-2025 | Vraylar, Qulipta, Linzess |
| Novartis Pharmaceuticals Corporation | $2,981.74 | 2019-2025 | |
| Allergan, INC. | $1,606.61 | 2020-2021 | |
| Lilly USA, LLC | $1,423.21 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Genentech USA, INC. | $1,409.43 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,171.23 | 2019-2025 | Farxiga, Breztri, Tezspire |
| Senseonics, Incorporated | $1,150.00 | 2019-2020 | |
| Glaxosmithkline, LLC. | $904.89 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $777.05 | 2019-2025 | |
| Abbott Laboratories | $586.59 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $584.66 | 2019-2025 | Jardiance, Jascayd |
| Novo Nordisk INC | $443.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $409.07 | 2019-2022 | |
| Merz North America, INC. | $399.64 | 2019-2021 | |
| Ardelyx, INC. | $317.22 | 2024-2025 | Ibsrela |
Show all 64 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,948,641.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamran Tasharofi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.